Hoth Therapeutics, Inc. (HOTH)
NASDAQ: HOTH · IEX Real-Time Price · USD
+0.020 (1.72%)
Apr 23, 2024, 11:18 AM EDT - Market open

Company Description

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs.

It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.

The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device.

The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003.

Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.

Hoth Therapeutics, Inc.
Hoth Therapeutics logo
Country United States
Founded 2017
IPO Date Feb 15, 2019
Industry Biotechnology
Sector Healthcare
Employees 2
CEO Robb Knie

Contact Details

590 Madison Avenue, 21st Floor
New York, New York 10022
United States
Phone (646)756-2997

Stock Details

Ticker Symbol HOTH
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $5.60
CIK Code 0001711786
CUSIP Number 44148G105
ISIN Number US44148G2049
Employer ID 82-1553794
SIC Code 2834

Key Executives

Name Position
Robb Knie President, Chief Executive Officer and Chairman
David S. Briones Chief Financial Officer
Hayley Springer Executive Vice President of Operations

Latest SEC Filings

Date Type Title
Apr 22, 2024 424B3 Prospectus
Apr 19, 2024 EFFECT Notice of Effectiveness
Apr 11, 2024 S-1 General form for registration of securities under the Securities Act of 1933
Mar 28, 2024 10-K Annual Report
Mar 28, 2024 424B3 Prospectus
Mar 28, 2024 8-K Current Report
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 9, 2024 8-K Current Report
Nov 13, 2023 10-Q Quarterly Report
Oct 5, 2023 8-K Current Report